We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partner and internally.
Partnerships Sinntaxis AB: option and collaboration agreement (Apr 30, 2025) for exclusive license to IP covering mGlu5 inhibitors in brain injury recovery plus research collaboration; economics not disclosed
Indications
Post-stroke/TBI recovery(Stage not disclosed)
Status note Lead development compound per this filing. Further in vivo testing in stroke models ongoing; Phase 2a start planned subject to funding or securing a development partner (no date stated).
ADX71149
Phase 2 · ActiveModality: small molecule (orally active PAM)
Target mGlu2
Partnerships Janssen (terminated): development terminated Jul 22, 2024; partnership agreement terminated Apr 17, 2025 with program and IP returned to Addex
Indications
Indication under evaluation(Stage not disclosed)
Status note Janssen terminated development (Jul 22, 2024) after Phase 2 did not support continued development; partnership terminated Apr 17, 2025 and program returned to Addex. Company currently evaluating future development.
GABAB PAM (Indivior-selected compound)
Preclinical · Active
Target GABAB
Partnerships Indivior: worldwide rights licensed; Indivior selected compound Aug 27, 2024 and completed IND-enabling studies May 12, 2025; Indivior responsible for all development, manufacture and commercialization; milestones and royalties in USD (amounts not disclosed)
Indications
Substance use disorder (SUD)(Preclinical)
Status note IND-enabling studies completed by Indivior May 12, 2025. All future development undertaken by Indivior.
GABAB PAM (Addex chronic cough program)
Discovery · Active
Target GABAB
Partnerships n/a (independent program; rights retained under Indivior agreement)
Indications
Chronic cough(Stage not disclosed)
Status note Selected compound; in late clinical candidate selection phase. IND-enabling studies planned subject to securing funding or a development partner (no date stated).
M4 PAM (Neurosterix program)
Phase 1 · Active
Target M4
Partnerships Neurosterix (spin-out; Addex holds 20% equity interest and received CHF 5.0M cash on divestiture Apr 2, 2024; Addex does not control development)
Indications
Schizophrenia(Phase 1)
Status note Lead program of spin-out Neurosterix, advancing through Phase 1 clinical studies. Addex holds a 20% equity interest only; not an Addex-operated pipeline program.
Per-asset detail extracted from the 20-F filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.